• DSMZ and P.H.A.G.E. are cooperating in order to establish a Therapeutic Phage Bank, a collection of phages being in focus of potential application.
  • 1
  • 2

P.H.A.G.E. Who we are

We are an international non-profit organization to support phage research and phage therapy in Europe.

Read More

Literature For Expert Reading

Our collection of Literature can surely interest you.

Read More

P.H.A.G.E. How we work

Want to know more about PHAGE as non-profit organization...

Read More

In June 2016, a 61-year-old man was hospitalised for Enterobacter cloacae peritonitis and severe abdominal sepsis with disseminated intravascular coagulation, secondary to a diaphragmatic hernia with bowel strangulation. The patient had a prolonged hospital course complicated by gangrene of the peripheral extremities, resulting in the amputation of the lower limbs and the development of large necrotic pressure sores.

Three months after admission, the patient was transferred to the Queen Astrid military hospital for surgical management of the pressure sores. Wound cultures on admission revealed colonisation with, amongst others, multidrug-resistant P. aeruginosa. One month after admission, the patient developed septicaemia with colistin-only-sensitive P. aeruginosa. Intravenous colistin therapy was started.

Bacteriophages are increasingly put forward as safe alternatives or additions to antibiotic therapy. Historical reports show that they were efficaciously used via the intravenous route, especially in typhoid fever and Staphylococcus aureus bacteremia, but this is—as far as we know—the first contemporary report of intravenous bacteriophage monotherapy against P. aeruginosa septicaemia in humans.

More information